Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Philip A Beer"'
Autor:
Hélène Asnagli, Norbert Minet, Christina Pfeiffer, Eef Hoeben, Rebecca Lane, David Laughton, Louise Birch, Geraint Jones, Andrew Novak, Andrew E. Parker, Heinz Ludwig, Alain Fischer, Sylvain Latour, Philip A. Beer
Publikováno v:
HemaSphere, Vol 7, Iss 4, p e864 (2023)
Lymphoma is the most common hematological malignancy and is among the 10 most prevalent cancers worldwide. Although survival has been improved by modern immunochemotherapeutic regimens, there remains a significant need for novel targeted agents to tr
Externí odkaz:
https://doaj.org/article/94c683a95284402c9f04f59bf749bdad
Autor:
Rebecca Caeser, Miriam Di Re, Joanna A. Krupka, Jie Gao, Maribel Lara-Chica, João M. L. Dias, Susanna L. Cooke, Rachel Fenner, Zelvera Usheva, Hendrik F. P. Runge, Philip A. Beer, Hesham Eldaly, Hyo-Kyung Pak, Chan-Sik Park, George S. Vassiliou, Brian J. P. Huntly, Annalisa Mupo, Rachael J. M. Bashford-Rogers, Daniel J. Hodson
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
A dearth of adequate preclinical models to faithfully mimic diffuse large B-cell lymphoma has hampered the identification of driver genes. Here, the authors present a co-culture system that enables ex vivo expansion, viral transduction and transforma
Externí odkaz:
https://doaj.org/article/d3c9bc11a5cc4cb39c1c847ddd0e75b2
Autor:
Simon Crouch, Daniel Painter, Sharon L. Barrans, Eve Roman, Philip A. Beer, Susanna L. Cooke, Paul Glover, Suzan J.L. Van Hoppe, Nichola Webster, Stuart E. Lacy, Camilo Ruiz, Peter J. Campbell, Daniel J. Hodson, Russell Patmore, Cathy Burton, Alexandra Smith, Reuben M. Tooze
Publikováno v:
Blood Advances. 6:5716-5731
Follicular lymphoma (FL) is morphologically and clinically diverse, with mutations in epigenetic regulators alongside t(14;18) identified as disease-initiating events. Identification of additional mutational entities confirms this cancer’s heteroge
Autor:
Raymond Henderson, Richard Sullivan, Denis Horgan, Philip A. Beer, Mark Lawler, Kathi Apostolides, Nicola Normanno, Francesco De Lorenzo, Andrew V. Biankin
Publikováno v:
Seminars in Cancer Biology. 84:293-301
Cancer Biomarkers are the key to unlocking the promise of precision oncology, selecting which patients will respond to a more personalised treatment while sparing non-responders the therapy-related toxicity. In this paper, we highlight the primacy of
Autor:
Ignacio I. Wistuba, Hilary McElwaine-Johnn, David Vining, Graciela M. Nogueras-Gonzalez, Elisabeth A. Bone, Helen Berryman, Lucy Coe, Franck A. Silva, Kemal Haque, James Dow, Alexander R.L. Cecil, Simin Kiany, Henry H. Vo, Cara Haymaker, Carrie A. Cartwright, Philip A. Beer, Apostolia M. Tsimberidou
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::317fa511ab6534bc011525e90147418f
https://doi.org/10.1158/1078-0432.22480343.v1
https://doi.org/10.1158/1078-0432.22480343.v1
Autor:
Ignacio I. Wistuba, Hilary McElwaine-Johnn, David Vining, Graciela M. Nogueras-Gonzalez, Elisabeth A. Bone, Helen Berryman, Lucy Coe, Franck A. Silva, Kemal Haque, James Dow, Alexander R.L. Cecil, Simin Kiany, Henry H. Vo, Cara Haymaker, Carrie A. Cartwright, Philip A. Beer, Apostolia M. Tsimberidou
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d26f8db429394eb60f6de8e2974307d
https://doi.org/10.1158/1078-0432.22480346
https://doi.org/10.1158/1078-0432.22480346
Autor:
Ignacio I. Wistuba, Hilary McElwaine-Johnn, David Vining, Graciela M. Nogueras-Gonzalez, Elisabeth A. Bone, Helen Berryman, Lucy Coe, Franck A. Silva, Kemal Haque, James Dow, Alexander R.L. Cecil, Simin Kiany, Henry H. Vo, Cara Haymaker, Carrie A. Cartwright, Philip A. Beer, Apostolia M. Tsimberidou
Purpose:Inhibition of histone deacetylase 6 (HDAC6) is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response. This study describes the development of a novel HDAC6 inhibitor.Patients and Methods:KA2507 wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19858b5e25a20b1e682ee91ab8838811
https://doi.org/10.1158/1078-0432.c.6530423
https://doi.org/10.1158/1078-0432.c.6530423
Autor:
Fieke E.M. Froeling, Sarah Bradley, Judith Dixon, Rosie Upstill-Goddard, Paul Grimwood, Paul Westwood, Andrew V. Biankin, Philip A. Beer, Janet Graham, Juan Valle, David K. Chang
Publikováno v:
Pancreatology. 23:e4-e5
Autor:
Philip A. Beer, David J.H.F. Knapp, Nagarajan Kannan, Paul H. Miller, Sonja Babovic, Elizabeth Bulaeva, Nima Aghaeepour, Gabrielle Rabu, Shabnam Rostamirad, Kingsley Shih, Lisa Wei, Connie J. Eaves
Publikováno v:
Stem Cell Reports, Vol 3, Iss 5, Pp 841-857 (2014)
Disrupted IKAROS activity is a recurrent feature of some human leukemias, but effects on normal human hematopoietic cells are largely unknown. Here, we used lentivirally mediated expression of a dominant-negative isoform of IKAROS (IK6) to block norm
Externí odkaz:
https://doaj.org/article/debcf6b44d1540b1884cfae480c423c6
Autor:
Apostolia Maria Tsimberidou, Cara Haymaker, Franck Alexandre Silva, Simin Kiany, Kemal Haque, Lucy Coe, Carrie Cartwright, Helen Berryman, Graciela M. Nogueras-Gonzalez, James Dow, David Vining, Alexander Richard Liam Cecil, Henry H. Vo, Elisabeth A. Bone, Ignacio I. Wistuba, Philip A. Beer, Hilary McElwaine-Johnn
Publikováno v:
Clinical Cancer Research. 27:3584-3594
Purpose: Inhibition of histone deacetylase 6 (HDAC6) is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response. This study describes the development of a novel HDAC6 inhibitor. Patients and Methods: KA2507